Targeting of Memory T Cells With Alefacept in New-Onset Type 1 Diabetes (T1DAL Study): 12 Month Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Study Questions:

What is the effect of alefacept on autoimmunity and preservation of residual β cells in patients newly diagnosed with type 1 diabetes?